Neuroendocrinology · 2017 · 23 citations · 30 references
MedicineNuclear MedicineOncologyDiagnostic ImagingDiagnostic RadiologyThoracic ImagingCancer DetectionLung CancerOncologic Nuclear ImagingPositron Emission TomographyThoracic Oncology ImagingTumor ImagingDecay-corrected Standardized Uptake ValueGallium-68 Dotatate PetGallium-68 Somatostatin Analogue Positron Emission TomographyLung Tumor ImagingMedian AgePulmonary Carcinoid TumorsSomatostatin Receptor PetSomatostatin Receptor Scintigraphy
BACKGROUND: 68Gallium DOTA-PET imaging is preferable to standard somatostatin receptor scintigraphy where available; however, its role in the management of lung carcinoid tumours (LC) remains unclear. METHODS: All consecutive patients with histologically confirmed LC from two ENETS Centres of Excellence were identified retrospectively. The primary objective was to assess the impact of 68Ga-DOTANOC-PET on clinical management in patients with LC. RESULTS: Of 166 patients screened, 46 were eligible: 52% female, median age 57 years (range 21-86); type of LC: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (4%), typical (44%), atypical (35%), not reported (17%); stage: localised (63%), locally advanced (13%), and metastatic (17%) (7% unknown). A total of 47 68Ga-DOTANOCs were performed with the following rationale: LC diagnosis confirmation (4; 9%), primary tumour identification (2; 4%), post-surgical assessment (19; 40%), staging (patients with known LC present at time of 68Ga-DOTANOC) (19; 40%), and consideration of peptide receptor radionuclide therapy (3; 7%). Twenty-seven (57%) scans showed evidence of non-physiological uptake: median maximum standardised uptake value 7.2 (range 1.42-53). 68Ga-DOTANOC provided additional information in 37% (95% CI 22-51) of patients and impacted on management in 26% (95% CI 12-41); 9 patients (21%) were identified to have occult sites of metastases. Out of the 19 patients with post-surgical 68Ga-DOTANOC, 3 (16%) were identified to have distant metastases. There were no differences in the rate of practice changing 68Ga-DOTANOC results by type of LC (p value 0.5). CONCLUSIONS: Our results support the role of 68Ga-DOTANOC for optimising the management of patients with LC, including post-surgical re-staging due to the potential for identifying occult metastases.
30
A 5‐decade analysis of 13,715 carcinoid tumors
Irvin M. Modlin, Kevin D. Lye, Mark Kidd · Cancer · 2003 · 2.7K citations
Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Anna Imhof, Philippe Brunner, Nicolas Marincek et al. · Journal of Clinical Oncology · 2011 · 621 citations
Medicine, Oncology, Pharmacology +17